Association between Bone Marrow Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography and Response to Chemotherapy in Non-Small Cell Lung Cancer.
- Author:
Hee Yun SEOL
1
;
Jeong Ha MOK
;
Seong Hoon YOON
;
Ji Eun KIM
;
Ki Uk KIM
;
Hye Kyung PARK
;
Seong Jang KIM
;
Yun Seong KIM
;
Min Ki KIM
;
Soon Kew PARK
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung cancer; Bone marrow; (18)F-Fluorodeoxyglucose positron emission tomography; Chemotherapy
- MeSH: Bone Marrow; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Electrons; Humans; Liver; Logistic Models; Lumbar Vertebrae; Multivariate Analysis; Positron-Emission Tomography
- From:Tuberculosis and Respiratory Diseases 2009;66(1):20-26
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for the diagnosis and staging of non-small cell lung cancer (NSCLC). The aim of this study is to determine whether the bone marrow hypermetabolism seen on FDG-PET predicts a response to chemotherapy in patients with NSCLC. METHODS: We evaluated the patients with advanced NSCLC and who were treated with combination chemotherapy. For determination of the standardized uptake value (SUV) of the bone marrow (BM SUV) on FDG-PET, regions of interest (ROIs) were manually drawn over the lumbar vertebrae (L1, 2, 3). ROIs were also drawn on a homogenous transaxial slice of the liver to obtain the bone marrow/ liver SUV ratio (BM/L SUV ratio). The response to chemotherapy was evaluated according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria after three cycles of chemotherapy. RESULTS: Fifty-nine NSCLC patients were included in the study. Multivariate analysis was performed using a logistic regression model. The BM SUV and the BM/L SUV ratio on FDG-PET were not associated with a response to chemotherapy in NSCLC patients (p=0.142 and 0.978, respectively). CONCLUSION: The bone marrow hypermetabolism seen on FDG-PET can not predict a response to chemotherapy in NSCLC patients.
